Lifesci Capital Reaffirms “Market Perform” Rating for Nuvalent (NASDAQ:NUVL)

Nuvalent (NASDAQ:NUVL)‘s stock had its “market perform” rating reiterated by Lifesci Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $124.00 price objective on the stock. Lifesci Capital’s target price points to a potential upside of 0.92% from the stock’s current price.

A number of other analysts also recently issued reports on NUVL. Leerink Partners set a $165.00 price target on Nuvalent in a research report on Wednesday, June 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Nuvalent in a report on Tuesday, June 2nd. Wells Fargo & Company assumed coverage on Nuvalent in a report on Monday, March 30th. They issued an “overweight” rating and a $116.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $155.00 price target on shares of Nuvalent in a research report on Tuesday, April 21st. Finally, Sanford C. Bernstein initiated coverage on shares of Nuvalent in a report on Thursday, May 21st. They issued an “outperform” rating and a $189.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.22.

Nuvalent Price Performance

Shares of Nuvalent stock opened at $122.87 on Tuesday. The stock has a fifty day moving average price of $102.38 and a 200-day moving average price of $102.97. Nuvalent has a 1 year low of $71.13 and a 1 year high of $122.83. The firm has a market cap of $9.71 billion, a PE ratio of -20.28 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same period in the prior year, the firm posted ($1.18) earnings per share. As a group, equities analysts anticipate that Nuvalent will post -5.74 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Henry E. Pelish sold 3,093 shares of the business’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $104.48, for a total value of $323,156.64. Following the transaction, the insider owned 65,604 shares of the company’s stock, valued at approximately $6,854,305.92. The trade was a 4.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Deborah Ann Miller sold 5,500 shares of Nuvalent stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $107.84, for a total transaction of $593,120.00. Following the completion of the sale, the insider owned 59,634 shares in the company, valued at approximately $6,430,930.56. This represents a 8.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 96,953 shares of company stock valued at $9,956,364 over the last three months. Insiders own 5.02% of the company’s stock.

Hedge Funds Weigh In On Nuvalent

Several hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC boosted its position in Nuvalent by 64.8% in the 1st quarter. AQR Capital Management LLC now owns 9,874 shares of the company’s stock valued at $700,000 after buying an additional 3,881 shares during the period. Goldman Sachs Group Inc. increased its holdings in Nuvalent by 54.4% during the first quarter. Goldman Sachs Group Inc. now owns 453,620 shares of the company’s stock valued at $32,171,000 after buying an additional 159,873 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Nuvalent by 8.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 149,941 shares of the company’s stock worth $10,634,000 after buying an additional 12,123 shares during the period. Intech Investment Management LLC boosted its position in Nuvalent by 28.7% during the 1st quarter. Intech Investment Management LLC now owns 19,262 shares of the company’s stock valued at $1,366,000 after acquiring an additional 4,293 shares in the last quarter. Finally, Prudential Financial Inc. purchased a new position in shares of Nuvalent in the 2nd quarter valued at $412,000. Institutional investors own 97.26% of the company’s stock.

Key Headlines Impacting Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK agreed to buy Nuvalent for $10.6 billion, giving NUVL shareholders a large acquisition premium and effectively taking the company private. Reuters: UK’s GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
• Positive Sentiment: The deal validates Nuvalent’s oncology assets, including experimental lung cancer therapies that have attracted enough interest to prompt a major strategic acquisition. WSJ: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
• Neutral Sentiment: Several reports noted that the deal is part of GSK’s push to strengthen its oncology pipeline and offset future patent pressure elsewhere in its business. Proactive Investors: GSK agrees $10.6bn Nuvalent takeover to bolster oncology pipeline
• Neutral Sentiment: Some market commentary suggested investors were more focused on GSK’s valuation impact than on Nuvalent itself, but the transaction still confirms the stock’s upside is now tied to deal completion. Invezz: GSK’s $10.6B Nuvalent takeover fails to impress investors as shares fall

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.